MWM
VRTX icon

Meridian Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Meridian Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Sell
742
-86
-10% -$38.1K 0.01% 627
2026
Q1 		$370K Buy
828
+18
+2% +$8.39K 0.01% 601
2025
Q4 		$367K Buy
810
+101
+14% +$43.5K 0.01% 568
2025
Q3 		$278K Buy
709
+2
+0.3% +$836 0.01% 598
2025
Q2 		$315K Buy
707
+87
+14% +$40.1K 0.01% 547
2025
Q1 		$301K Buy
620
+1
+0.2% +$466 0.01% 520
2024
Q4 		$249K Buy
619
+14
+2% +$6.49K 0.01% 557
2024
Q3 		$281K Buy
605
+19
+3% +$9.13K 0.01% 533
2024
Q2 		$275K Buy
+586
New +$254K 0.03% 246
2024
Q1 		– Sell
-794
Closed -$323K – 557
2023
Q4 		$323K Buy
794
+31
+4% +$11.5K 0.02% 487
2023
Q3 		$265K Sell
763
-19
-2% -$6.64K 0.02% 470
2023
Q2 		$275K Buy
782
+1
+0.1% +$337 0.02% 457
2023
Q1 		$246K Sell
781
-29
-4% -$8.7K 0.02% 470
2022
Q4 		$234K Buy
810
+25
+3% +$7.62K 0.02% 462
2022
Q3 		$227K Sell
785
-165
-17% -$47.5K 0.02% 430
2022
Q2 		$268K Buy
+950
New +$254K 0.02% 455
2021
Q1 		– Sell
-3,319
Closed -$784K – 377
2020
Q4 		$784K Sell
3,319
-338
-9% -$77.6K 0.12% 141
2020
Q3 		$995K Buy
3,657
+131
+4% +$36.1K 0.24% 83
2020
Q2 		$1.02M Buy
3,526
+145
+4% +$39.3K 0.34% 66
2020
Q1 		$804K Buy
+3,381
New +$776K 0.36% 60
2019
Q3 		– Sell
-140
Closed -$25.7K – 496
2019
Q2 		$25.7K Buy
+140
New +$24.5K 0.01% 495

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Meridian Wealth Management's VRTX Position: Q2 2026 in Review

Meridian Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 10% in Q2 2026, selling an estimated $38.1K and leaving 742 shares worth $369K. The position accounts for 0.01% of the portfolio, ranked #627.

Meridian Wealth Management first reported a position in VRTX in Q2 2019 and has held it in 21 quarters since. The position peaked at $1.02M in Q2 2020. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Meridian Wealth Management held 742 shares of Vertex Pharmaceuticals worth $369K as of Q2 2026.
  • Meridian Wealth Management sold 86 Vertex Pharmaceuticals shares in Q2 2026, an estimated $38.1K.
  • Vertex Pharmaceuticals made up 0.01% of Meridian Wealth Management's portfolio in Q2 2026, its #627 holding.
  • Meridian Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 21 quarters since.
  • Meridian Wealth Management's Vertex Pharmaceuticals position peaked at $1.02M in Q2 2020.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Meridian Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.